MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
6.35
+0.31
+5.13%
Closed 16:00 03/27 EDT
OPEN
6.07
PREV CLOSE
6.04
HIGH
6.73
LOW
6.02
VOLUME
195.94K
TURNOVER
0
52 WEEK HIGH
8.19
52 WEEK LOW
1.574
MARKET CAP
271.38M
P/E (TTM)
-6.0574
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at HOWL last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at HOWL last week (0311-0315)?
Weekly Report · 03/18 09:07
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
NASDAQ · 03/12 13:55
Weekly Report: what happened at HOWL last week (0304-0308)?
Weekly Report · 03/11 09:07
Buy Rating Affirmed for Werewolf Therapeutics with Anticipated Surge on WTX-124 Phase 1 Data Release
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on Werewolf Therapeutics stock, giving a Buy rating on March 7. The analyst expects updated Phase 1 data to be released in the first half of 2024. The company's lead cytokine candidate, WTX-124, is being developed to treat cancer.
TipRanks · 03/11 04:47
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
Werewolf Therapeutics reported earnings per share of -33 cents. The company reported revenue of $1.50 million. This was 22.63% worse than the analyst estimate for the company to report revenue of -35 million. The stock was down 2.7% after the market closed.
Investorplace · 03/07 19:52
Werewolf Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 17:09
Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/07 17:09
More
About HOWL
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.